Business Context and Reporting Period
This Form 8-K, dated October 30, 2020, reports the confirmation of an Amended Joint Plan of Reorganization for BioRestorative Therapies, Inc. (the "Company") by the United States Bankruptcy Court for the Eastern District of New York. The Company filed for Chapter 11 bankruptcy on March 20, 2020, and has been operating as a debtor-in-possession. The Confirmation Order entered on October 30, 2020, finalizes the reorganization plan filed with the Court.
Key Financial Metrics and Capital Structure
The filing details the restructuring of debt and equity rather than reporting standard operating metrics like revenue or net income for a specific period.
- Debt Restructuring: The Company's largest unsecured creditor, Auctus Fund, LLC ("DIP Lender"), provided up to $7,000,000 in debtor-in-possession (DIP) financing. This obligation is being exchanged for a Secured Convertible Note equal to 110% of the DIP Obligation, plus Class A and Class B Warrants.
- New Funding Commitment: Upon the Plan's effectiveness, Auctus is committed to infusing not less than $3,500,000 in new funding. Additional funding of up to $3,500,000 (less the DIP Obligation) is subject to the Company becoming current in SEC filings.
- Other Creditor Treatment: Specific secured notes held by John Desmarais totaling approximately $353,762 are being exchanged for a Secured Convertible Note of $490,698.81. Other unsecured claims are being satisfied via stock issuance or convertible notes.
- Equity Structure: As of the Confirmation Order, 1,639,203,270 shares of Common Stock were issued and outstanding. An additional 1,058,993,393 shares were reserved for issuance under the Plan, bringing the aggregate total to 2,698,196,663 shares. The authorized share count is increased to 300,000,000,000 with a par value reduction to $0.0001.
Material Changes Versus Prior Period
The primary material change is the legal confirmation of the Chapter 11 reorganization plan, transitioning the Company from a pending bankruptcy case to a confirmed reorganization structure. Key changes include:
- Debt-to-Equity Conversion: Significant portions of unsecured debt are being converted into Common Stock or convertible notes, fundamentally altering the capital structure.
- Shareholder Rights: Pre-petition holders of Common Stock, options, and warrants retain their interests, but all antidilution rights and rights to sell or put shares to the Company are extinguished and cancelled.
- Liquidity Injection: The confirmation secures a minimum of $3,500,000 in new funding from Auctus, contingent on the Plan's effectiveness.
Guidance, Outlook, Risks, and Contingencies
Outlook and Conditions: The Company's ability to access the full $3,500,000 in additional new funding is contingent upon becoming current in its SEC periodic filings and meeting other customary conditions. The Company cautions that financial projections included in the Disclosure Statement were not audited and should not be relied upon as indicative of future results.
Risks and Contingencies:
- Bankruptcy Risks: Risks include the effects of the Chapter 11 case on operations, potential third-party motions, and the possibility that financing conditions may not be satisfied.
- Market Risks: The Company faces risks related to the trading price and volatility of its common stock on the OTC Market's Pink tier.
- Forward-Looking Statements: The filing includes standard disclaimers that forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from projections.
Investor Verification Checklist
- Verify the Company's status regarding SEC periodic filings to confirm eligibility for the additional $3,500,000 funding tranche.
- Review the "Schedules of Assets and Liabilities" (Exhibit 99.1) for a complete picture of the Company's financial position.
- Confirm the exact amount of the DIP Obligation to calculate the principal amount of the Secured Convertible Note (110% of the obligation).
- Monitor the trading status of the Common Stock on the OTC Market's Pink tier and any potential listing on the Nasdaq Capital Market, which would trigger mandatory conversion of notes.
- Examine the leak-out restrictions on shares issued to unsecured creditors, which limit sales to 33% during the first three 30-day periods post-Effective Date.